Sunday 16 August 2020
Books – Sayed Metwally
A warning issued by French Health Minister Olivier Ferrand at the beginning of the Corona virus outbreak raised global concerns about medicines, including painkillers.
Minister Olivier Ferrand wrote on Twitter: “Taking anti-inflammatory drugs (ibuprofen and cortisone) may be among the factors that aggravate the enemy. If you have a high temperature, you should take paracetamol.”
“Masrawy” reveals the fact that taking “ibuprofen” increases the risk of death from “Corona”, according to the British newspaper “The Sun”.
It seems that this is not true, after a British study revealed that taking painkillers such as ibuprofen does not increase the risk of death from Covid-19.
Researchers at the University of Aberdeen have now confirmed that the fears are unfounded, and have assessed the outcome of 1,222 patients who were admitted to eight British hospitals at the height of the epidemic.
Of these, 54 non-steroidal inflammatory drugs were routinely prescribed, such as ibuprofen, naproxen and diclofenac, the death rate for those who took the pills was similar to the patients who did not take the drugs.
Scientists say these drugs may slightly reduce the risk of death, but the sample size of people tested was too small to be confirmed.
“Our results do not show any significant negative effect of the use of routine NSAIDs on mortality in patients with Covid-Corona infection,” said study leader Dr. Elide Bruce.
“In fact, there might be a beneficial effect on the routine use of NSAIDs on the mortality rate, but the sample size was not sufficient to draw conclusions about that,” she adds.
“More evidence is needed to explore this potential link,” she continues. “NSAIDs are one of the most commonly prescribed and used pain medications worldwide, for both acute pain and chronic conditions such as rheumatism and arthritis.”
She concluded: “Based on our findings, patients and physicians should not link the routine use of NSAIDs to an increased risk of death in Covid-19 disease, and therefore we recommend that patients continue to comply with their primary medication regimen.”